How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the first CRISPR-based medicine expected to win FDA approval any minute now, STAT’s Megan Molteni joins us to discuss how we got here and what it means for the future. Then, Bruce Booth from Atlas Venture joins us to discuss what was yet another downbeat year for biotech and whether there’s reason for optimism heading into 2024. For more on what we cover, here’s more on Casgevy came to be; here’s the story on its fertility concerns; here’s the AbbVie news; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout. Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts. And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
This content was originally published here.
